Pulmo BioTech Inc. Completes Bio-Distribution Studies

    NEW YORK, July 7 /CNW/ -- Pulmo BioTech Inc. (OTC Bulletin Board:  
PLMO.OB) has announced that its subsidiary, PulmoScience Inc. has completed
the bio-distribution studies on its DFH-12 product candidate for the PulmoBind
technology of Molecular Imaging of the vascular system of the lungs.
    Molecular Imaging uses a molecule designed to bond specifically to
certain parts of the body. In the case of PulmoBind, the chosen molecule was
designed to bond only to the inner walls of the vascular system of the lungs.
Because the molecule (code named DFH-12) is tagged with a radionuclide, the
integrity of the lung's vascular system can then be imaged using the Gamma
Cameras which are typically available in all hospitals with a Nuclear Medicine
    It is important for diagnostic image quality that the PulmoBind molecule
is only retained in the lungs, and we are very pleased to announce that in-
vivo studies have shown that the molecule is predominantly retained in the
lungs 30 minutes after injection with only minor retention (~ 1/10th) in the
liver and heart. It is equally important that after imaging the molecule is
quickly eliminated from the body and further bio-distribution studies have
show that after 240 minutes the majority of the injected molecules have been
eliminated through the kidneys and bladder.

    About Pulmo BioTech Inc.

    Pulmo BioTech Inc. specializes in the development and marketing of
medical technology and research. Our proven strengths combine extensive
commercial experience and academic credentials. The principal staff members
are acknowledged experts in their specialized fields, and work with a broad
range of investment institutions.  Our mission is to utilize scientific
imagination and drive, together with managerial and financial acumen, to bring
innovative and profitable products to the marketplace to the benefit of all
stock holders.

    About PulmoScience Inc.

    PulmoScience Inc. was established in 2006, and is currently developing a
non-invasive Molecular Imaging technique for the diagnosis of Pulmonary
Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the
trade name PulmoBind.
    PulmoScience was conceived within the Montreal Heart Institute "MHI" (a
world renowned hospital and educational facility). Jointly owned by MHI
subsidiary Innovacor as the technical and operational partner, Dr Jocelyn
Dupuis (the scientific director and originator of the PulmoBind Molecular
Imaging technology), and by Pulmo BioTech Inc. as the funding partner,
PulmoScience Inc. aims to develop this unique and exciting technology, to fund
necessary trials, and to bring the products to market.
    PulmoScience believes that the market for its product candidates is worth
in excess of $500 million per annum and that, provided Regulatory Approval is
achieved, the safety and efficacy of its products could allow it to dominate
that market.

    About PulmoBind

    PulmoBind uses an intravenously delivered radionuclide tagged molecule
which specifically bonds to the inner walls of the circulatory system in the
lungs, and by the use of an external Gamma Camera allows an image of the
integrity of the blood vessels throughout the lungs to be seen by a diagnostic
clinician. PulmoScience is currently undertaking Regulatory Approval for Phase
I Human Trials, and, while subsequent results from additional tests might not
corroborate the current results, PulmoScience believes that PulmoBind has the
potential to dominate the market for the diagnosis of Pulmonary Embolism. In
particular, this belief is driven by PulmoScience's expectations of the
improved safety and efficacy that PulmoBind will offer when compared to the
current incumbent nuclear medicine based technology for the diagnosis of
Pulmonary Embolism. In addition, early indications are that PulmoBind could be
highly effective in the early stage diagnosis of Pulmonary Hypertension, a
condition for which there is no current front line diagnostic test. The
addressable market for the product candidates being developed by PulmoScience
is believed by the company to be worth in excess of $500 million per annum.

    Forward-Looking Statements

    Forward-looking statements contained in this and other written and oral
reports are made based on known events and circumstances at the time of
release, and as such, are subject in the future to unforeseen uncertainties
and risks. All statements regarding future performance, earnings projections,
regulatory approval, events or developments are forward-looking statements. It
is possible that the future performance of the company may differ materially
from current expectations, depending on economic conditions and the
uncertainty of regulatory approval. A change in economic conditions may have a
particularly volatile effect on results. Among the other factors which may
affect future performance are: competitive market conditions and resulting
effects on sales and pricing; increases in raw-material costs that cannot be
recovered in product pricing; and global economic factors, including
difficulties entering new markets and general economic conditions such as
inflation, interest rates and credit availability. The company makes these
statements as of the date of this disclosure, and undertakes no obligation to
update them.

For further information:

For further information: Peter B. Hirshfield, (646) 827-9362,
phirshfield@hirshfieldlaw.com, for Pulmo BioTech Inc.

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890